127 related articles for article (PubMed ID: 38483112)
1. Use of Lentivirus-Based Method for Establishing TK6 Human Cell Lines Expressing Cytochrome P450 and its Applications in Genotoxicity Testing.
Li X; Chen S; He X; Wu Q; Guo L; Mei N
Curr Protoc; 2024 Mar; 4(3):e1003. PubMed ID: 38483112
[TBL] [Abstract][Full Text] [Related]
2. Development and Application of TK6-derived Cells Expressing Human Cytochrome P450s for Genotoxicity Testing.
Li X; Chen S; Guo X; Wu Q; Seo JE; Guo L; Manjanatha MG; Zhou T; Witt KL; Mei N
Toxicol Sci; 2020 Jun; 175(2):251-265. PubMed ID: 32159784
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
Wu Y; Chitranshi P; Loukotková L; Gamboa da Costa G; Beland FA; Zhang J; Fang JL
Arch Toxicol; 2017 Jun; 91(6):2405-2423. PubMed ID: 27896399
[TBL] [Abstract][Full Text] [Related]
4. The genotoxicity potential of luteolin is enhanced by CYP1A1 and CYP1A2 in human lymphoblastoid TK6 cells.
Li X; He X; Chen S; Le Y; Bryant MS; Guo L; Witt KL; Mei N
Toxicol Lett; 2021 Jun; 344():58-68. PubMed ID: 33727136
[TBL] [Abstract][Full Text] [Related]
5. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.
Fujita K; Kamataki T
Mutat Res; 2001 Nov; 483(1-2):35-41. PubMed ID: 11600130
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pyrrolizidine alkaloid-induced genotoxicity using metabolically competent TK6 cell lines.
Li X; He X; Chen S; Guo X; Bryant MS; Guo L; Manjanatha MG; Zhou T; Witt KL; Mei N
Food Chem Toxicol; 2020 Nov; 145():111662. PubMed ID: 32798647
[TBL] [Abstract][Full Text] [Related]
7.
Lim SYM; Alshagga MA; Alshawsh MA; Ong CE; Pan Y
Drug Metab Pers Ther; 2021 Aug; 37(1):55-67. PubMed ID: 35146975
[TBL] [Abstract][Full Text] [Related]
8. Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s.
Li X; He X; Le Y; Guo X; Bryant MS; Atrakchi AH; McGovern TJ; Davis-Bruno KL; Keire DA; Heflich RH; Mei N
Arch Toxicol; 2022 Nov; 96(11):3077-3089. PubMed ID: 35882637
[TBL] [Abstract][Full Text] [Related]
9. Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase.
Fujita K; Kamataki T
Environ Mol Mutagen; 2001; 38(4):339-46. PubMed ID: 11774366
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
11. Serum derived from ulcerative colitis mouse changes the metabolism of the fluorescent substrate by P450 depending on the degree of disease progression.
Yamamoto R; Muroi K; Imaishi H
Chem Biol Interact; 2018 Jun; 290():88-98. PubMed ID: 29842871
[TBL] [Abstract][Full Text] [Related]
12. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies.
Kranendonk M; Carreira F; Theisen P; Laires A; Fisher CW; Rueff J; Estabrook RW; Vermeulen NP
Mutat Res; 1999 Apr; 441(1):73-83. PubMed ID: 10224324
[TBL] [Abstract][Full Text] [Related]
13. The expression of Phase II drug-metabolizing enzymes in human B-lymphoblastoid TK6 cells.
Li X; Li Y; Ning KG; Chen S; Guo L; Bonzo JA; Mei N
J Environ Sci Health C Toxicol Carcinog; 2022; 40(1):106-118. PubMed ID: 35895929
[TBL] [Abstract][Full Text] [Related]
14. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s.
Styles JA; Davies A; Lim CK; De Matteis F; Stanley LA; White IN; Yuan ZX; Smith LL
Carcinogenesis; 1994 Jan; 15(1):5-9. PubMed ID: 8293548
[TBL] [Abstract][Full Text] [Related]
15. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro.
Chang SY; Chen C; Yang Z; Rodrigues AD
Drug Metab Dispos; 2009 Aug; 37(8):1667-75. PubMed ID: 19454483
[TBL] [Abstract][Full Text] [Related]
16. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
Environ Mol Mutagen; 2001; 38(4):329-38. PubMed ID: 11774365
[TBL] [Abstract][Full Text] [Related]
17. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
[TBL] [Abstract][Full Text] [Related]
18. Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
Chamboko CR; Veldman W; Tata RB; Schoeberl B; Tastan Bishop Ö
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834793
[TBL] [Abstract][Full Text] [Related]
19. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology.
Yoshitomi S; Ikemoto K; Takahashi J; Miki H; Namba M; Asahi S
Toxicol In Vitro; 2001 Jun; 15(3):245-56. PubMed ID: 11377097
[TBL] [Abstract][Full Text] [Related]
20. Effect of eurycomanone on cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 in vitro.
Pan Y; Tiong KH; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Ong CE
J Nat Med; 2014 Apr; 68(2):402-6. PubMed ID: 23881640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
